← Leaderboards
Joel Moss
Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Reporting”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Jeffrey P Krischer · University Of South Florida$564,567,727
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Bambra Strokes · Ppd Development Lp$461,655,950
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
ReportingCellsGenesProteinsLungAffectAdp RibosylationAnnual ReportsBaseExhibitsBacterial ToxinsPathway InteractionsLymphangioleiomyomatosisMutationFamilyPathogenesisSignal TransductionLoss Of HeterozygosityCell ProliferationTumorModificationReactionArginineAmino Acids
Grant awards (68)
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,648,863
ZIA · FY2025 · HL · contact PI
ADP-ribosylation Cycles$1,594,783
ZIA · FY2025 · HL · contact PI
Clinical and Translational Research$72,297
ZIA · FY2025 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,941,694
ZIA · FY2024 · HL · contact PI
ADP-ribosylation Cycles$1,591,105
ZIA · FY2024 · HL · contact PI
Clinical and Translational Research$69,380
ZIA · FY2024 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,116,742
ZIA · FY2023 · HL · contact PI
ADP-ribosylation Cycles$1,388,014
ZIA · FY2023 · HL · contact PI
Clinical and Translational Research$68,600
ZIA · FY2023 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,503,531
ZIA · FY2022 · HL · contact PI
ADP-ribosylation Cycles$1,676,104
ZIA · FY2022 · HL · contact PI
Clinical and Translational Research$123,260
ZIA · FY2022 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,633,037
ZIA · FY2021 · HL · contact PI
ADP-ribosylation Cycles$1,818,115
ZIA · FY2021 · HL · contact PI
Clinical and Translational Research$129,636
ZIA · FY2021 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,992,416
ZIA · FY2020 · HL · contact PI
ADP-ribosylation Cycles$2,066,266
ZIA · FY2020 · HL · contact PI
Clinical and Translational Research$147,330
ZIA · FY2020 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,363,729
ZIA · FY2019 · HL · contact PI
ADP-ribosylation Cycles$2,142,144
ZIA · FY2019 · HL · contact PI
Clinical and Translational Research$143,187
ZIA · FY2019 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,551,929
ZIA · FY2018 · HL · contact PI
ADP-ribosylation Cycles$2,302,339
ZIA · FY2018 · HL · contact PI
Clinical and Translational Research$195,186
ZIA · FY2018 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$1,938,066
ZIA · FY2017 · HL · contact PI
ADP-ribosylation Cycles$1,136,382
ZIA · FY2017 · HL · contact PI
Clinical and Translational Research$94,238
ZIA · FY2017 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$1,152,435
ZIA · FY2016 · HL · contact PI
ADP-ribosylation Cycles$587,158
ZIA · FY2016 · HL · contact PI
Clinical and Translational Research$83,880
ZIA · FY2016 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,278,235
ZIA · FY2015 · HL · contact PI
ADP-ribosylation Cycles$1,226,742
ZIA · FY2015 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,162,086
ZIA · FY2014 · HL · contact PI
ADP-ribosylation Cycles$2,201,133
ZIA · FY2014 · HL · contact PI
Clinical and Translational Research$370,391
ZIA · FY2014 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,314,109
ZIA · FY2013 · HL · contact PI
ADP-ribosylation Cycles$2,329,449
ZIA · FY2013 · HL · contact PI
Clinical and Translational Research$378,142
ZIA · FY2013 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,174,487
ZIA · FY2012 · HL · contact PI
ADP-ribosylation Cycles$2,664,079
ZIA · FY2012 · HL · contact PI
Clinical and Translational Research$385,918
ZIA · FY2012 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$3,094,983
ZIA · FY2011 · HL · contact PI
ADP-ribosylation Cycles$2,465,873
ZIA · FY2011 · HL · contact PI
Clinical and Translational Research$318,670
ZIA · FY2011 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,413,413
ZIA · FY2010 · HL · contact PI
ADP-ribosylation Cycles$1,479,189
ZIA · FY2010 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,437,131
ZIA · FY2009 · HL · contact PI
ADP-ribosylation Cycles$1,134,049
ZIA · FY2009 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,100,780
Z01 · FY2008 · HL · contact PI
ADP-ribosylation Cycles$988,602
Z01 · FY2008 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)$2,368,990
Z01 · FY2007 · HL · contact PI
ADP-ribosylation Cycles$1,064,329
Z01 · FY2007 · HL · contact PI
Characterization of the Pathogenesis of Lymphangioleiomy$0
Z01 · FY2006 · HL · contact PI
ADP-ribosylation Cycles$0
Z01 · FY2006 · HL · contact PI
ADP-ribosylation Cycles$0
Z01 · FY2005 · HL
Characterization of the Pathogenesis of Lymphangioleiomy$0
Z01 · FY2005 · HL
Characterization of the Pathogenesis of Lymphangioleiomy$0
Z01 · FY2004 · HL
ADP-ribosylation Cycles$0
Z01 · FY2004 · HL
Characterization of the Pathogenesis of Lymphangioleiomy$0
Z01 · FY2003 · HL
ADP-ribosylation Cycles$0
Z01 · FY2003 · HL
Characterization Of The Pathogenesis Of Lymphangioleiomy$0
Z01 · FY2002 · HL
Adp-ribosylation Cycles$0
Z01 · FY2002 · HL
Characterization Of The Pathogenesis Of Lymphangioleiomy$0
Z01 · FY2001 · HL
Adp-ribosylation Cycles$0
Z01 · FY2001 · HL
ADP-RIBOSYLATION CYCLES$0
Z01 · FY2000 · HL
CHARACTERIZATION OF THE PATHOGENESIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM)$0
Z01 · FY2000 · HL
ROLE OF NITRIC OXIDE IN THE PATHOGENESIS OF LUNG DISEASE$0
Z01 · FY2000 · HL
CHARACTERIZATION OF MAMMALIAN ADP-RIBOSYLTRANSFERASES$0
Z01 · FY2000 · HL